论文部分内容阅读
目的：观察环孢素 A（CsA）治疗系统性红斑狼疮（SLE）相关难治性血小板减少的长期疗效及安全性。方法对我科收治的16例 SLE 相关难治性血小板减少患者使用 CsA 治疗，并长期随访观察 CsA 的疗效及不良反应。结果显效8例，有效6例，总有效率为87．5%。有效的14例患者随访（38±2．5）个月，治疗3月平均血小板值（137．9±64．1）×109/ L，随访过程中各患者最低血小板值（85．4±39．5）×109/ L，与用 CsA 治疗前相比差异均有统计学意义（P ＜0．001），且未见严重不良反应。结论小剂量 CsA 是治疗 SLE 相关难治性血小板减少的一种安全、有效的方法，不良反应轻微。“,”Objective To observe the efficacy and safety of cyclosporin_A(CsA)in the treatment of thrombocytopenia associated with systemic lupus erythematosus. Methods 16 systemic lupus erythematosus(SLE)patients with severe thrombo_cytopenia received no response after corticosteroids(CS)combined several immunosuppressive agents,then treated with CsA, observing the efficacy and side effects in the long_term follow up. Results The course of the follow up range 10 monthes to 6 years. A complete response was observed in 8 patients;a partial response in 6 patients. All these 14 patients achieved long_term remission. No severe side effects were observed. Conclusion CsA can be applied as an effective and safe therapeutic option for refractory SLE_related thrombocytopenia.